AC Immune SA (ACIU) said Tuesday that it will receive a second milestone payment of 24.6 million Swiss francs ($29.1 million) under its agreement with Johnson & Johnson (JNJ) subsidiary Janssen Pharmaceuticals.
The milestone payment follows the rapid rate of prescreening in a trial of JNJ-2056 to treat preclinical Alzheimer's disease, AC Immune said.
Shares of AC Immune were up about 8% in Tuesday's premarket activity.
Price: 3.5300, Change: +0.26, Percent Change: +7.95
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。